The American Cancer Society is now directly urging men to get screened for prostate cancer every two years starting at age 50 — a stark reversal from years of equivocation that left millions of men untested while the medical establishment chased other priorities.
Prostate cancer kills more American men than any cancer except lung cancer. For over a decade, the country's leading health organizations told doctors and patients to figure it out themselves. Men didn't get tested. Late-stage diagnoses climbed. Now the ACS is racing to undo the damage.
The updated guidelines, published Thursday in CA: A Cancer Journal for Clinicians, replace the old "shared decision-making" framework — which effectively meant a lot of men were simply never offered the test. "Leaving it to each patient and doctor meant a lot of men were simply never offered the test. A clear recommendation fixes that," said Dr. Neeraj Agarwal, a medical oncologist at the Dana-Farber Cancer Institute/Harvard Cancer Center, who was not involved in the guideline update.
Under the new rule: average-risk men should get a PSA blood test every two years starting at 50. Black men and men with a father or brother diagnosed before 65 should start annual screening at 45. Men 70 to 74 go back to the old "discuss with your doctor" standard.
The shift is rooted in long-term European trial data showing men screened every two years had a measurable drop in prostate cancer mortality. Dr. William Dahut, chief scientific officer of the ACS, said the previous guideline, published in 2010, reflected a time when "it wasn't really clear at that point that with prostate screening, the benefits outweigh the harms." He said improved screening techniques and long-term survival data changed the calculus.
What neither outlet dwells on is how we got here. The FDA approved the PSA test for cancer surveillance in 1986. Late-stage diagnoses and death rates dropped. Then, in the 2000s, health authorities panicked about overdiagnosis. In 2012, the U.S. Preventive Services Task Force recommended against PSA testing for men of any age. As NBC reported, diagnoses of late-stage disease subsequently began to creep up. An ACS study found prostate cancer diagnoses increasing by about 3% annually from 2014 on.
So the same institutional medicine that spent a decade telling men the test might do more harm than good — while simultaneously declaring puberty blockers and cross-sex hormones for minors to be "gender-affirming care" — now admits the test saves lives. Real medicine for real men was sidelined while the establishment prioritized ideology. Men paid the price.
Dr. Yaw Nyame of the Fred Hutchinson Cancer Center, who served on the expert panel reviewing the guidelines, emphasized the value of early baseline testing: "Your first PSA can be really powerful, especially when obtained in your 40s and 50s. It establishes a baseline. If that first PSA is under 1 ng/ml, your lifetime risk of prostate cancer is much lower."
The new guideline sets an abnormal PSA threshold at 3 nanograms per milliliter or higher for men 69 and younger, and 6.5 ng/mL or higher for men 70 to 74. Elevated PSA doesn't always mean cancer — it can reflect an enlarged prostate or infection — but it flags who needs follow-up.
The death rate from prostate cancer fell by half over the past three decades, but that decline has slowed and stabilized among men 55 to 69. The medical establishment is now playing catch-up with a disease it chose to deprioritize. The open question is how many men were lost in the years the experts couldn't make up their minds.
